News
PLUR
5.73
-2.05%
-0.12
Weekly Report: what happened at PLUR last week (0708-0712)?
Weekly Report · 3d ago
Pluri Announced €1M Proof Of Concept Agreement To Enhance Global Sustainable Vegetable Supply
Pluri Inc. Has announced a strategic proof of concept agreement with a leading international agriculture corporation. The agreement is intended to boost the global vegetable product supply, streamline supply chains, and combat global climate change. Pluri transforms cells into solutions that promote global wellbeing and sustainability.
Benzinga · 07/08 11:06
Weekly Report: what happened at PLUR last week (0701-0705)?
Weekly Report · 07/08 10:49
Pluri Inc. Announces CFO Transition and New Appointment
TipRanks · 07/02 11:01
Weekly Report: what happened at PLUR last week (0624-0628)?
Weekly Report · 07/01 10:50
Weekly Report: what happened at PLUR last week (0617-0621)?
Weekly Report · 06/24 10:56
Consumer Sector Update for 06/18/2024: PLUR, CZR, MCD, F
NASDAQ · 06/18 19:44
Pluri: Biotech Play With Several Opportunities Across Different Sectors
Seeking Alpha · 06/18 16:45
Pluri subsidiary Ever After Foods secures $10M strategic investment
Pluri subsidiary Ever After Foods secures $10M strategic investment. Pluri (PLUR) shares rose +9.71% to $5.76 premarket. The biotechnology company reported strategic investments in its subsidiary, ever after foods Ltd. Ever after foods offers a technology platform to produce cultivated food with cost-efficient scalability.
Seeking Alpha · 06/18 11:24
Pluri Subsidiary Ever After Foods Secured $10 Million Strategic Investment to Solve Cultivated Food Scalability Challenges
Pluri's Ever After Foods Ltd. Offers a cutting-edge technology platform to produce cultivated food with unmatched, cost-efficient scalability. The $10 million funding round will propel the company's technology platform. Ever after Foods is Pluri's joint venture with Israeli food giant Tnuva.
Barchart · 06/18 05:30
Weekly Report: what happened at PLUR last week (0610-0614)?
Weekly Report · 06/17 10:49
Weekly Report: what happened at PLUR last week (0603-0607)?
Weekly Report · 06/10 10:50
Pluri Says US NIAID Will Provide Company With $1.4M From July 1, 2024 To June 30, 2025; NIAID Exercised Its Option For Year Two Of The Three-year $4.2M Contract It Entered Into With Pluri In July 2023
Benzinga · 06/06 10:50
U.S. National Institutes of Health Exercises Option to Fund $1.4 Million 2nd Year Budget for Pluri’s PLX-R18 Acute Radiation Syndrome Contract
The U.S. National Institute of Allergy and Infectious Diseases has exercised its option for year two of the three-year contract it entered into with Pluri in July 2023. The NIAID will provide $1.4 million for the Company to develop the PLX-R18 cell therapy. Pluri is developing a potential treatment for the acute radiation syndrome.
Barchart · 06/06 05:45
Weekly Report: what happened at PLUR last week (0527-0531)?
Weekly Report · 06/03 10:53
Weekly Report: what happened at PLUR last week (0520-0524)?
Weekly Report · 05/27 10:57
Weekly Report: what happened at PLUR last week (0513-0517)?
Weekly Report · 05/20 10:51
Weekly Report: what happened at PLUR last week (0506-0510)?
Weekly Report · 05/13 10:59
Pluri Inc. Quarterly Report Under Section 13 or 15(d) of the Securities Exchange Act of 1934 for the Quarterly Period Ended March 31, 2024
Press release · 05/10 18:04
Weekly Report: what happened at PLUR last week (0429-0503)?
Weekly Report · 05/06 11:05
More
Webull provides a variety of real-time PLUR stock news. You can receive the latest news about PLURILOCK SEC INC through multiple platforms. This information may help you make smarter investment decisions.
About PLUR
Pluri Inc., formerly known as Pluristem Therapeutics Inc., is an Israel-headquartered company engaged in the research and provision of cell-based products directed for a range of industries. The Company is focused on researching and developing cell transformation and 3D cell expansion technologies that allow mass production of cells. The products of the Company are used for the pharmaceutical industry as well as for food technology, agriculture technology, and cell-based materials. In the pharmaceutical sector, the Company's preclinical and clinical programs explore multiple therapeutic areas such as vascular disease, inflammation-related conditions, muscle injuries, and hematological disorders. In the food sector, the Firm produces cultivated meat, cultivated fish, and seafood, as well as plant-based products. In agriculture, the Company develops alternative farming methods. The Company has a portfolio of over 140 granted patents in approximately 52 countries.